1. Utomilumab: production of IFN-γ and IL-2; stimulate and increase NK cells and T cells 2. PF-04518600: co-stimulate effector T cells and deplete regulatory T cells, resulting in enhanced tumor immunity 3. CMP-001: release the oligonucleotide into APCs. This evidence concerns the gene IFNG and neoplasm.